Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Analyzing potential molecular reasons, we found in RP-PCa and RP-BPH in comparison to TUR-BPH a significant hypomethylation of IGF2-DMR0, which coincided with hypermethylation of GSTP1-promoter, a prominent marker of prostate tumors.
|
29017567 |
2017 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Somatic mutations in the genomes of prostate tumors have been repeatedly reported to include deletion and gain of the 8p and 8q chromosomal regions, respectively; epigenetic gene silencing of glutathione S-transferase Pi(GSTP1); as well as mutations in androgen receptor gene.
|
22085526 |
2012 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.
|
22581815 |
2012 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer.
|
19223546 |
2009 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Among these genes was the known candidate prostate tumor suppressor GSTP1 (involved in xenobiotic detoxification).
|
18500686 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells.
|
18413363 |
2008 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
|
17960617 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In prostate tumors, expression of GST pi (encoded by GSTP1) is frequently lost because of promoter hypermethylation.
|
17415778 |
2007 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The silencing of GSTP1, due to aberrant methylation at the CpG island in the promoter/5'-UTR, occurs in the vast majority of prostate tumors and precancerous lesions.
|
16921492 |
2007 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
|
17291695 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.
|
17453001 |
2007 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism.
|
17067754 |
2006 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Gene promoter methylation in prostate tumor-associated stromal cells.
|
16478744 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
|
15538743 |
2005 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
From the translational standpoint, we should make an effort to validate the use of some hypermethylated genes as biomarkers of the disease; for example, it may occur with MGMT and GSTP1 in brain and prostate tumors, respectively.
|
15822191 |
2005 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
|
15538743 |
2005 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer.
|
15527908 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma.
|
15328191 |
2004 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer.
|
12746833 |
2003 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of glutathione S-transferase pi (GSTP1), a detoxification enzyme that also binds steroid hormones, is diminished or absent in human prostate tumors possibly because of promoter hypermethylation.
|
11796315 |
2002 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The CpG island-associated with the GSTP1 gene is an intriguing example of a CpG rich region which is susceptible to hypermethylation in the majority of prostate tumours and yet is unmethylated in the normal prostate cell.
|
11850822 |
2002 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
|
11751372 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1.
|
11196146 |
2001 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Methylation-specific polymerase chain reaction (MSP) targeting promoter hypermethylation of the glutathione S transferase P1 gene (GSTP1), as the most frequent DNA alteration in prostatic carcinoma, was used for the molecular detection of cell-bound and cell-free prostate tumor DNA in various human bodily fluids.
|
11708494 |
2001 |